SG157224A1
(en)
|
2001-11-13 |
2009-12-29 |
Univ Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
AU2013202568B2
(en)
*
|
2001-11-13 |
2015-09-17 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus rh.8 (AAVrh.8) sequences and recombinant AAVs comprising same
|
EP1453547B1
(en)
|
2001-12-17 |
2016-09-21 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
|
US20070015238A1
(en)
*
|
2002-06-05 |
2007-01-18 |
Snyder Richard O |
Production of pseudotyped recombinant AAV virions
|
DK3211085T3
(da)
*
|
2003-09-30 |
2021-06-21 |
Univ Pennsylvania |
Klader af adeno-associeret virus (aav), sekvenser, vektorer indeholdende disse og anvendelser deraf
|
WO2005049850A2
(en)
|
2003-11-14 |
2005-06-02 |
University Of Washington |
Compositions and methods for systemic nucleic acid sequence delivery
|
EP2007795B1
(en)
*
|
2006-03-30 |
2016-11-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Aav capsid proteins
|
US9198984B2
(en)
|
2006-04-28 |
2015-12-01 |
The Trustees Of The University Of Pennsylvania |
Scalable production method for AAV
|
US20120322861A1
(en)
|
2007-02-23 |
2012-12-20 |
Barry John Byrne |
Compositions and Methods for Treating Diseases
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
DK2191001T3
(en)
|
2007-04-09 |
2016-09-19 |
Univ Florida |
RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
|
EP2019143A1
(en)
*
|
2007-07-23 |
2009-01-28 |
Genethon |
CNS gene delivery using peripheral administration of AAV vectors
|
EP2058401A1
(en)
*
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
JP2011512326A
(ja)
*
|
2007-12-31 |
2011-04-21 |
ナノコア セラピューティクス,インコーポレイテッド |
心不全の治療用のrna干渉
|
MX2010012592A
(es)
|
2008-05-20 |
2011-05-05 |
Eos Neuroscience Inc |
Vectores para la administracion de proteinas sensibles a la luz y metodos de uso de las mismas.
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
US9415121B2
(en)
|
2008-12-19 |
2016-08-16 |
Nationwide Children's Hospital |
Delivery of MECP2 polynucleotide using recombinant AAV9
|
LT2424991T
(lt)
|
2009-05-02 |
2018-09-25 |
Genzyme Corporation |
Neurodegeneracinių sutrikimų genų terapija
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
CA2793633A1
(en)
|
2010-03-29 |
2011-10-13 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
EP3444346B1
(en)
|
2010-04-23 |
2022-07-27 |
University of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
DK2561073T3
(en)
|
2010-04-23 |
2016-12-12 |
Univ Massachusetts |
Aav vectors targeted to central nervous system and methods of use thereof
|
CA3128549A1
(en)
|
2010-07-12 |
2012-01-19 |
Universitat Autonoma De Barcelona |
Gene therapy composition for use in diabetes treatment
|
JP6042825B2
(ja)
*
|
2011-02-10 |
2016-12-14 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法
|
WO2012145624A2
(en)
|
2011-04-21 |
2012-10-26 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
US8559100B2
(en)
|
2011-10-12 |
2013-10-15 |
Guardian Industries Corp. |
Coated article with low-E coating having absorbing layer over functional layer designed to increase outside reflectance
|
WO2013103896A1
(en)
|
2012-01-06 |
2013-07-11 |
Mayo Foundation For Medical Education And Research |
Treating cardiovascular or renal diseases
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
MX2014015985A
(es)
|
2012-06-19 |
2015-07-21 |
Univ Florida |
Composiciones y metodos para tratar enfermedades.
|
JP6314138B2
(ja)
|
2012-08-01 |
2018-04-18 |
ネイションワイド チルドレンズ ホスピタル |
組換えアデノ随伴ウイルス9の髄腔内送達
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
EP2749569A1
(en)
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variant of BPIFB4 protein
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
HUE051311T2
(hu)
|
2014-03-09 |
2021-03-01 |
Univ Pennsylvania |
Ornitin transzkarbamiláz (TC) deficiencia kezelésében alkalmas készítmények
|
CA2942289C
(en)
|
2014-03-10 |
2024-05-21 |
Uniqure Ip B.V. |
Further improved aav vectors produced in insect cells
|
WO2015143078A1
(en)
|
2014-03-18 |
2015-09-24 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
EP3194430A1
(en)
|
2014-09-16 |
2017-07-26 |
Universitat Autònoma De Barcelona |
Adeno-associated viral vectors for the gene therapy of metabolic diseases
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
CA2964272A1
(en)
|
2014-10-21 |
2016-04-28 |
Guangping Gao |
Recombinant aav variants and uses thereof
|
BR112017009497A2
(pt)
|
2014-11-05 |
2018-02-06 |
Voyager Therapeutics, Inc. |
polinucleotídeos de aadc para o tratamento da doença de parkinson
|
KR20230145206A
(ko)
|
2014-11-14 |
2023-10-17 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
BR112017010087A2
(pt)
|
2014-11-14 |
2018-06-05 |
Voyager Therapeutics, Inc. |
composições e métodos para tratar esclerose lateral amiotrófica (ela)
|
MX2017006652A
(es)
|
2014-11-21 |
2017-08-21 |
Univ North Carolina Chapel Hill |
Vectores de virus adeno-asociado (aav) dirigidos al sistema nervioso central.
|
EP3230441A4
(en)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
EP3233131A1
(en)
|
2014-12-16 |
2017-10-25 |
Board of Regents of the University of Nebraska |
Gene therapy for juvenile batten disease
|
EP3978614A3
(en)
|
2015-01-07 |
2022-07-27 |
Universitat Autònoma de Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
CA2970730A1
(en)
|
2015-01-16 |
2016-07-21 |
Voyager Therapeutics, Inc. |
Central nervous system targeting polynucleotides
|
WO2016126857A1
(en)
|
2015-02-03 |
2016-08-11 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
MA41451A
(fr)
|
2015-02-04 |
2017-12-12 |
Univ Washington |
Constructions anti-tau
|
EP3256170B1
(en)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
US10017832B2
(en)
|
2015-08-25 |
2018-07-10 |
Washington University |
Compositions and methods for site specific recombination at asymmetric sites
|
SG10202107733QA
(en)
|
2015-09-28 |
2021-09-29 |
Univ North Carolina Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
EP3364996B1
(en)
|
2015-10-22 |
2021-08-25 |
University of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
US11253576B2
(en)
|
2015-10-22 |
2022-02-22 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
BR112018008407A2
(pt)
|
2015-10-28 |
2018-11-27 |
Univ Pennsylvania |
administração intratecal de vetores virais adenoassociados para terapia genética
|
AU2016362477A1
(en)
|
2015-12-02 |
2018-06-14 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
EP3992283A1
(en)
|
2015-12-11 |
2022-05-04 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
EP3387117B1
(en)
|
2015-12-11 |
2022-11-23 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
WO2017160360A2
(en)
|
2015-12-11 |
2017-09-21 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
US11938193B2
(en)
|
2016-01-08 |
2024-03-26 |
Washington University |
Compositions comprising chemerin and methods of use thereof
|
EP3411059A4
(en)
|
2016-02-02 |
2019-10-16 |
University Of Massachusetts |
METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
WO2017147509A1
(en)
|
2016-02-25 |
2017-08-31 |
Marco Colonna |
Compositions comprising trem2 and methods of use thereof
|
WO2017176929A1
(en)
|
2016-04-05 |
2017-10-12 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
EP3443001A4
(en)
|
2016-04-11 |
2020-04-29 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
US11433116B2
(en)
|
2016-04-14 |
2022-09-06 |
Cedars-Sinai Medical Center |
GJA1 isoforms protect against metabolic stress
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
EP3448987A4
(en)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR THE TREATMENT OF DISEASES
|
MA44740A
(fr)
|
2016-05-13 |
2019-02-27 |
4D Molecular Therapeutics Inc |
Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
|
RU2764587C2
(ru)
|
2016-05-18 |
2022-01-18 |
Вояджер Терапьютикс, Инк. |
Способы и композиции для лечения хореи гентингтона
|
MX2018014154A
(es)
|
2016-05-18 |
2019-05-06 |
Voyager Therapeutics Inc |
Polinucleotidos moduladores.
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
MX2019000962A
(es)
|
2016-07-26 |
2019-08-01 |
Biomarin Pharm Inc |
Novedosas proteinas de la capside del virus adenoasociado.
|
EP3831281A1
(en)
|
2016-08-30 |
2021-06-09 |
The Regents of The University of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
US11111271B2
(en)
|
2016-09-28 |
2021-09-07 |
Cohbar, Inc. |
Therapeutic peptides
|
EP3526333A4
(en)
|
2016-10-13 |
2020-07-29 |
University of Massachusetts |
AAV CAPSIDE DESIGNS
|
JP7106534B2
(ja)
|
2016-11-17 |
2022-07-26 |
ネイションワイド チルドレンズ ホスピタル, インコーポレイテッド |
メチル-cpg結合タンパク質2をコードする組換えアデノ随伴ウイルスの髄腔内送達
|
MX2019006426A
(es)
|
2016-12-01 |
2019-08-14 |
Sangamo Therapeutics Inc |
Reguladores de tau, y composiciones y metodos para su administracion.
|
US11117930B2
(en)
|
2017-02-23 |
2021-09-14 |
Adrx, Inc. |
Peptide inhibitors of transcription factor aggregation
|
EP3619308A4
(en)
|
2017-05-05 |
2021-01-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT FOR HUNTINGTON'S MORBUS
|
AU2018261790A1
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
JP7327803B2
(ja)
|
2017-05-09 |
2023-08-16 |
ユニバーシティ オブ マサチューセッツ |
筋萎縮性側索硬化症(als)を処置する方法
|
CA3066077A1
(en)
|
2017-06-07 |
2018-12-13 |
Adrx, Inc. |
Tau aggregation inhibitors
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
WO2019018342A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
NETWORK EQUIPMENT TRACK GUIDE SYSTEM
|
WO2019028306A2
(en)
|
2017-08-03 |
2019-02-07 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES
|
ES2970198T3
(es)
|
2017-08-16 |
2024-05-27 |
Lgv1 S R L |
Isoforma VTFT de una proteína BPIFB4 para uso en enfermedades y lesiones neuronales
|
PT3684423T
(pt)
|
2017-09-20 |
2023-06-09 |
4D Molecular Therapeutics Inc |
Cápsides variantes de vírus adeno-associado e métodos de utilização das mesmas
|
AU2018338188A1
(en)
|
2017-09-22 |
2020-04-02 |
University Of Massachusetts |
SOD1 dual expression vectors and uses thereof
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
EP4124658A3
(en)
|
2017-10-16 |
2023-04-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
SG11202003479TA
(en)
*
|
2017-10-18 |
2020-05-28 |
Regenxbio Inc |
Fully-human post-translationally modified antibody therapeutics
|
SG11202004406VA
(en)
|
2017-11-08 |
2020-06-29 |
Avexis Inc |
Means and method for preparing viral vectors and uses of same
|
EP3717636B1
(en)
|
2017-11-27 |
2023-03-08 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
KR20200110376A
(ko)
|
2018-01-17 |
2020-09-23 |
아드레나스 테라퓨틱스, 인코포레이티드 |
21-하이드록실라제 결핍을 위한 아데노-관련 바이러스 유전자 요법
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
WO2019161365A1
(en)
|
2018-02-19 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof
|
WO2019195449A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
US20220025396A1
(en)
*
|
2018-05-07 |
2022-01-27 |
Spark Therapeutics, Inc. |
Plasmid free aav vector producing cell lines
|
AU2019265560A1
(en)
|
2018-05-09 |
2020-11-26 |
Biomarin Pharmaceutical Inc. |
Methods of treating phenylketonuria
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒(aav)之組成物和方法
|
SG11202011296VA
(en)
|
2018-05-15 |
2020-12-30 |
Voyager Therapeutics Inc |
Compositions and methods for the treatment of parkinson's disease
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
EP3807404A1
(en)
|
2018-06-13 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
JP2021530548A
(ja)
|
2018-07-24 |
2021-11-11 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. |
遺伝子治療製剤を生産するための系および方法
|
BR112021003897A2
(pt)
|
2018-08-30 |
2021-05-25 |
Tenaya Therapeutics, Inc. |
reprogramação de células cardíacas com miocarina e asci1
|
SG11202103151RA
(en)
|
2018-09-28 |
2021-04-29 |
Voyager Therapeutics Inc |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
US20210348194A1
(en)
|
2018-10-05 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
US20210395777A1
(en)
|
2018-10-15 |
2021-12-23 |
Voyager Therapeutics, Inc. |
EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
EP3870600A1
(en)
|
2018-10-24 |
2021-09-01 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
MX2021006359A
(es)
|
2018-11-30 |
2021-08-11 |
Novartis Ag |
Vectores virales de vaa y sus usos.
|
EP3911410A1
(en)
|
2019-01-18 |
2021-11-24 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
EP3917944A1
(en)
|
2019-01-28 |
2021-12-08 |
Cohbar Inc. |
Therapeutic peptides
|
US20230193315A1
(en)
|
2019-01-31 |
2023-06-22 |
Oregon Health & Science University |
Methods for using transcription-dependent directed evolution of aav capsids
|
JP2022520875A
(ja)
|
2019-02-25 |
2022-04-01 |
ノバルティス アーゲー |
Biettiクリスタリン網膜症を治療するための組成物及び方法
|
CA3130731A1
(en)
|
2019-02-25 |
2020-09-03 |
Friedrich Miescher Institute For Biomedical Research |
Compositions and methods to treat bietti crystalline dystrophy
|
MX2021011468A
(es)
|
2019-03-21 |
2021-12-15 |
|
Vectores de virus adenoasociados recombinantes.
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
EP3997226A1
(en)
|
2019-07-11 |
2022-05-18 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
JP2022540478A
(ja)
|
2019-07-12 |
2022-09-15 |
サンガモ セラピューティクス, インコーポレイテッド |
空のおよび完全なウイルスキャプシド粒子の分離および定量化
|
WO2021040736A1
(en)
|
2019-08-30 |
2021-03-04 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
WO2021072129A2
(en)
|
2019-10-08 |
2021-04-15 |
Trustees Of Boston College |
Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
|
WO2021076925A1
(en)
|
2019-10-17 |
2021-04-22 |
Stridebio, Inc. |
Adeno-associated viral vectors for treatment of niemann-pick disease type c
|
EP4073257A1
(en)
|
2019-12-09 |
2022-10-19 |
UCL Business Ltd |
Gene therapy composition and treatment for myh7-linked cardiomyopathy
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
IL295989A
(en)
|
2020-03-02 |
2022-10-01 |
Tenaya Therapeutics Inc |
Gene vector control using cardiomyocyte expression microRNA
|
US20230085724A1
(en)
|
2020-03-05 |
2023-03-23 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
BR112022020753A2
(pt)
|
2020-04-15 |
2022-12-20 |
Voyager Therapeutics Inc |
Compostos de ligação a tau
|
EP4146672A1
(en)
*
|
2020-05-04 |
2023-03-15 |
The University of North Carolina at Chapel Hill |
Modified adeno-associated virus vectors that evade neutralizing antibodies and uses thereof
|
EP4149955A1
(en)
|
2020-05-13 |
2023-03-22 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
MX2023000815A
(es)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composiciones y metodos para el tratamiento de trastornos neurologicos relacionados con la deficiencia de glucosilceramidasa beta.
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
US20240043494A1
(en)
|
2020-08-07 |
2024-02-08 |
Amicus Therapeutics, Inc. |
Vesicle Targeting Proteins And Uses Of Same
|
CN113754728B
(zh)
*
|
2020-09-30 |
2022-07-12 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
IL302109A
(en)
|
2020-10-15 |
2023-06-01 |
Prevail Therapeutics Inc |
Recombinant adeno-associated virus compositions and methods for their production
|
CA3209779A1
(en)
|
2021-02-01 |
2022-08-04 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
WO2022198038A1
(en)
|
2021-03-19 |
2022-09-22 |
Adrenas Therapeutics, Inc. |
Gene therapies for 21-hydroxylase deficiency
|
JP2024515623A
(ja)
|
2021-04-13 |
2024-04-10 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
髄腔内送達によってピット・ホプキンス症候群を治療するためのメチル-cpg結合タンパク質2をコードする組換えアデノ随伴ウイルス
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
WO2023279073A1
(en)
|
2021-07-01 |
2023-01-05 |
Amicus Therapeutics, Inc. |
Neurotensin variants and tagged proteins comprising neurotensin or sortilin propeptide
|
WO2023283649A1
(en)
|
2021-07-08 |
2023-01-12 |
Tenaya Therapeutics, Inc. |
Optimized expression cassettes for gene therapy
|
WO2023010120A2
(en)
*
|
2021-07-30 |
2023-02-02 |
University Of Florida Research Foundation, Incorporated |
Engineering aav vectors with improved cns targeting
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
IL310691A
(en)
|
2021-08-11 |
2024-04-01 |
Sana Biotechnology Inc |
Genetically modified primary cells for allogeneic cell therapy
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
EP4384544A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
WO2023064811A1
(en)
|
2021-10-12 |
2023-04-20 |
Aspa Therapeutics, Inc. |
Methods and compositions for treating leukodystrophies
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
TW202337476A
(zh)
|
2022-01-17 |
2023-10-01 |
瑞士商迪納柯公司 |
用於與肌肉萎縮蛋白有關之心肌病之基因療法組合物及治療
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023201207A1
(en)
|
2022-04-11 |
2023-10-19 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|